Edwards Lifesciences (EW) recently held its annual Asia Pacific Patient Experience event, spotlighting patient and caregiver perspectives on structural heart disease. For investors, the gathering raises questions about how patient engagement connects to Edwards Lifesciences stock. See our latest analysis for Edwards Lifesciences. At a share price of $89.83, Edwards Lifesciences has seen a 6.24% 30 day share price return and a 4.72% 90 day share price return, while the 1 year total shareholder...

STE enters fiscal 2027 with solid growth, recurring healthcare demand and better margins, but tariffs and investment needs temper the valuation case.

EW's TAVR and TMTT growth support its outlook, but currency pressure and intense competition remain key risks.

Edwards Lifesciences stock has delivered a 21.6% gain over the past three years, yet the valuation checks paint a less generous picture. The intrinsic value estimate from a Discounted Cash Flow (DCF) model indicates the shares are roughly fairly valued, while traditional market multiples lean expensive. Over the last three years, Edwards Lifesciences has returned 21.6%, which rewards patient holders but leaves fresh buyers needing to judge how much upside is left at today’s...

Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.

Edwards' 14% three-month rally reflects broad structural-heart growth, but its premium valuation raises the bar for execution.

Though Edwards Lifesciences has underperformed the broader market over the past year, Wall Street analysts maintain a strongly optimistic outlook on the stock’s prospects.

Intuitive Surgical's da Vinci 5 is gaining rapid adoption, fueling hospital upgrades as software enhancements build a potential multi-year capital cycle.

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]

Investors need to pay close attention to EW stock based on the movements in the options market lately.

Facing competition from Edwards, Abbott is studying TriClip’s real-world safety and performance in about 1,000 patients.

Intuit downgrade, Intuitive Surgical upgraded: Wall Street's top analyst calls

On July 23, Edwards Lifesciences Corporation (NYSE:EW) delivered second-quarter 2026 net sales of $1.74 billion, up 13.6% year over year (12.5% on a constant currency basis), surpassing Wall Street expectations of $1.70 billion. Adjusted diluted earnings per share came in at $0.78, ahead of the consensus estimate of $0.74 and up 16.4% from $0.67 a […]

Edwards Lifesciences stock sits at an interesting spot for valuation focused investors, with the Discounted Cash Flow (DCF) based intrinsic value estimate suggesting the shares are roughly in line with underlying cash flow assumptions, while the broader checks still point to a stock that does not screen as cheap and has delivered a decline over five years. Over the past 5 years, Edwards Lifesciences has delivered a total return that is down 26.4%, which raises the question of whether the...

SpaceX initiated, PayPal upgraded: Wall Street's top analyst calls

Edwards TAVR business contributed the lion’s share of its Q2 revenues at $1.26bn, largely informing its decision to uplift its 2026 revenue growth outlook.

EW beats Q2 earnings and revenue estimates as strong TAVR demand, and mitral and tricuspid therapy adoption lift results and guidance.

Moby summary of Edwards Lifesciences Corporation's Q2 2026 earnings call

An upcoming Medicare coverage decision for transcatheter aortic valve replacement devices and study readout for patients with moderate disease are expected to help the company maintain its momentum.

Edwards Lifesciences Corp (EW) reports a robust 12.5% sales increase, driven by innovation and strategic growth across key segments.

Edwards Lifesciences (NYSE:EW) reported stronger-than-expected second-quarter 2026 results, with management pointing to broad growth across transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies, and surgical products. Chief Executive Officer Bernard Zovighian said the

The headline numbers for Edwards Lifesciences (EW) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

The medical-technology company said it now expects sales of $6.6 billion to $6.9 billion for the full year, raising the bottom end of its prior range of $6.5 billion to $6.9 billion.

Edwards Lifesciences stock launched higher Thursday after the medtech company beat Wall Street's top- and bottom-line expectations.

EW heads into Q2 earnings results with estimates calling for double-digit revenue growth as TAVR, TMTT and Surgical heart businesses remain in focus.

The FTC secured the penalty after a court ruled that Edwards failed to comply with antitrust law requirements when it acquired JC Medical in 2024.

(Bloomberg) -- The Federal Trade Commission urged a judge to block Henkel AG’s $725 million purchase of part of Pittsburgh Paint Co., saying the deal would harm competition in the liquid-adhesive market by combining two of its biggest players.Most Read from BloombergLindsey Graham, Senate Hawk Turned Trump Ally, Dies at 71Trump Restarts Iran Blockade as US Plans 20% Hormuz ChargeTrump Embraces Australian Retirement System Backed by Larry FinkOpenAI Engineer’s ‘LOL’ Moment Set Stage for Legal Fig

The artificial heart valve maker will settle allegations it deliberately structured its deal to acquire JC Medical to sidestep a Hart-Scott-Rodino review.